Artiva Biotherapeutics (NASDAQ:ARTV) Trading 5.7% Higher – Time to Buy?

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) shot up 5.7% on Monday . The company traded as high as $11.55 and last traded at $11.5560. 160,571 shares traded hands during trading, a decline of 58% from the average session volume of 382,233 shares. The stock had previously closed at $10.93.

Analyst Ratings Changes

ARTV has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. HC Wainwright raised their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Trading Up 5.7%

The company has a market cap of $564.97 million, a PE ratio of -3.50 and a beta of 2.16. The business has a fifty day simple moving average of $10.17 and a two-hundred day simple moving average of $8.25.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting analysts’ consensus estimates of ($0.63). Equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 24,944 shares of Artiva Biotherapeutics stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $9.93 per share, for a total transaction of $247,693.92. Following the acquisition, the director owned 17,329,570 shares in the company, valued at approximately $172,082,630.10. This represents a 0.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 1,965,251 shares of company stock worth $16,188,035. 1.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently modified their holdings of ARTV. Alyeska Investment Group L.P. raised its position in shares of Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $2,910,000,000. 5AM Venture Management LLC acquired a new stake in Artiva Biotherapeutics during the second quarter worth about $22,827,049,000. ADAR1 Capital Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter valued at about $1,151,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at $8,483,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.